TrialBritish journal of haematology2026

MRD-negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD-positive after first-line therapy: Final analysis of the open-label, single-arm multicentric phase 2 trial DART4MM.

Alessandro Gozzetti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.